Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics

Eric Lawitz, Mark Sulkowski, Ira Jacobson, Walter K. Kraft, Benedict Maliakkal, Mohamed Al-Ibrahim, Stuart C. Gordon, Paul Kwo, Juergen Kurt Rockstroh, Paul Panorchan, Michelle Miller, Luzelena Caro, Richard Barnard, Peggy May Hwang, Jacqueline Gress, Erin Quirk, Niloufar Mobashery

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics'. Together they form a unique fingerprint.

Medicine & Life Sciences